Leadership

Dr. Feng is the Founder and Chief Executive Officer of Vesicor Therapeutics, Inc. Dr. Feng has over 30 years’ experience as a research scientist in cell and molecular biology. He has a strong background in studies of the cell cycle, DNA replication, regulation of gene expression, gene transfer with recombinant retrovirus, DNA-protein interactions, expertise in cloning, cell type-specific gene expression and gene transfection and transduction in mammalian systems. Dr. Feng has conducted research at the National Laboratory of Molecular Oncology at the Chinese Academy of Medical Sciences (CAMS) in Beijing, at the Saban Institute at Childrens Hospital of Los Angeles, at UCLA, and the Beckman Research Institute at City of Hope National Medical Center. In 2008, Dr. Feng founded RNTein Biotech Lab with the goal of commercializing microvesicle-based therapeutics. He has published extensively in multiple scientific journals. Dr. Feng has a BS degree in medical sciences from Anhui Medical College (Hefei, Anhui, China), a M.S. degree in biochemistry from the Cancer Institute of the Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC) in Beijing, and a Ph.D. in molecular biology from CAMS and PUMC. He was a postdoctoral fellow in the Department of Hematology and Oncology at Childrens Hospital of Los Angeles and completed further postdoctoral research in the Department of Molecular and Medical Pharmacology at UCLA.

Mr. Bowen has served as the Chief Financial Officer of Vesicor since February 2023. Prior to this, he served as the CFO of Accountable Healthcare America, Inc. since 2014. Michael Bowen has over 50 years of broad experience in the world of finance including public transactions such as initial public offerings, mergers and acquisitions, private equity transactions and extensive experience in international securities markets. For the past 10 years, Mr. Bowen has been Chief Financial Officer for a predecessor company of AHA and for AHA. He began his career at Goldman, Sachs & Co. in 1965 where he became a Vice President of the Corporate Finance Department and latterly helped establish the Tokyo office for Goldman Sachs. In 1976, he joined Salomon Brothers with the task of helping establish their first Asian office located in Hong Kong. He then moved to London to rebuild the International Capital Markets business for Chase Manhattan Ltd, the merchant banking arm of Chase Manhattan Bank where he was responsible for all of the international securities business of the bank/merchant bank. Mr. Bowen ended his international career as a Main Board Director for Kleinwort Benson, a British merchant bank where he was responsible for corporate finance business within the USA. Mr. Bowen returned to the US and in 2004 became CFO of TruBamboo, Inc. an innovative company selling bamboo houseware products to large US retailers. In 2008 he joined Diversified Health & Fitness as CFO and in 2014 became CFO of AHA. Mr. Bowen has an MBA from the Darden School of the University of Virginia and a BA also from the University of Virginia.